Online Issues
<< All Back-issues
<< This Issue's Table of Contents
ILAR Journal V40(4) 1999
Animal Models of Inflammation
Identification of a Transcription Factor (NFkB) Necessary for Development of Inflammatory Injury
Alex B. Lentsch and Peter A. Ward
| Alex B. Lentsch, Ph.D., is Assistant Professor in the Department of Surgery, University of Louisville School of Medicine, Louisville, Kentucky. Peter A. Ward, M.D., is Professor and Chairman of the Department of Pathology, The University of Michigan Medical School, Ann Arbor, Michigan. |
Introduction
Acute inflammation is a necessary response to tissue injury, designed to maintain homeostasis by returning the tissue to its preinjury state. In general, this response can be characterized as a cascade of events that result in complex, yet coordinated, interactions between blood leukocytes, blood vessels, and cells of the tissue(s) involved. These events are directed toward removal of injurious agents and restoration of normal tissue structure and/or function. However, dysregulated inflammatory processes cause many human diseases. Thus, successful development of therapeutic strategies to suppress undesirable inflammatory responses depends on two factors: (1) knowledge of the steps leading to activation of the inflammatory response and (2) an understanding of the regulatory mechanisms that serve to control the progression and/or resolution of the inflammatory response. Much has been learned about these two factors using rodent models of inflammation.
Lung inflammatory injury induced in rats by distal airway deposition of immunoglobulin G (IgG1) immune complexes has been used for many years for the study of lung inflammation (Johnson and Ward 1974). The inflammatory pathways in this particular model are rather similar to events related to lung injury caused by ischemia (Caty and others 1990), by the presence of bacteria (Lechner and others 1993), or by bacterial lipopolysaccharide (Simons and others 1996) and therefore represent a model relevant to human disease. In rats and mice, hepatic ischemia and repeffusion results in both local and remote organ inflammation (Colletti and others 1990a; Jaeschke and others 1990; Lentsch and others 1998a). These models are clinically relevant because liver resectional surgery (Huguet and others 1994), liver transplantation (Lemasters and Thurman 1997), and hemorrhagic shock with fluid resuscitation (Vedder and others 1989) are all complicated by inflammatory organ injury stemming from ischemic insult to the liver.
The inflammatory responses in lung and liver models share many similarities (Figure 1). The inflammatory insult causes complement activation as well as activation of tissue macrophages (Jaeschke and others 1993; Ward 1996). Activated macrophages generate the "early response" cytokines, tumor necrosis factor (TNF1)-a and interleukin (IL1)-1 (Colletti and others 1990b; Mulligan and Ward 1992). These cytokines stimulate vascular endothelial cells to express adhesion molecules (ICAM-1, E-selectin), which facilitate adhesion of blood neutrophils to the endothelium (Springer 1990). TNFa and IL-1 also stimulate the production of neu-trophil chemoattractants that are the chemokines of the IL-8 family of cytokines, from vascular endothelial cells and other tissue parenchymal cells (Schall and Bacon 1994). Vascular adhesion molecules and chemokines work in concert to bring about neutrophil transmigration from blood vessels to the tissue interstitium (Springer 1994). In organs such as lung and liver, the accumulation of neutrophils together with activated macrophages results in tissue injury mediated by the generation and release of oxidants and proteases (Jaeschke and others 1996; Varani and others 1989).
Regulation of Inflammatory Mediator Production by NFkB
Recently, a considerable amount of research has been aimed at the upstream, molecular mechanisms that regulate gene expression of proinflammatory mediators. Using monocyte and macrophage cell lines in vitro, the transcription factor nuclear factor kappa B (NFkB1) has been shown to be a major regulator of many functionally diverse proinflam-matory mediators. NFkB is a general term used to describe a number of dimeric combinations of members of the Rel family of gene regulatory proteins that possess transcriptional activating properties (Ghosh and others 1998). The most common form of NFkB consists of a heterodimer of p50 (NFkB1) and p65 (RelA) proteins. This complex has the ability to bind with promoter sequences in DNA and to inaugurate transcription (generation of mRNA) for many proinflammatory mediators. However, other combinations of Rel family members have been identified, and different configurations of Rel proteins (such as p65/p50 and p65/p52) may have preferential sensitivities to different target promoter sequences (Perkins and others 1992). In unstimulated cells, NFkB is retained in the cytoplasm through interactions with inhibitory proteins of the inhibitory factor kappa B (IkB1) family. To date, at least seven IkB proteins have been identified in vertebrates (Ghosh and others 1998). All IkB proteins contain ankyrin repeat domains, which function to facilitate protein-protein interactions. In the case of IkB/ NFkB interactions, ankyrin repeat domains of IkB proteins prevent nuclear translocation of NFkB by masking nuclear localization sequences of the NFkB (hetero)dimers. In response to a wide variety of cellular stimuli, IkB proteins are dissociated from the NFkB complex and then proteolytically degraded (Figure 2). This process varies for different IkB proteins but involves phosphorylation of IkB by members of the IkB-kinase (IKK) family (DiDonato and others 1997). Phosphorylation targets IkB for ubiquination and degradation by the 26S proteasome. Degradation of IkB leads to "activation" of NFkB, which is defined as translocation of the NFkB complex from the cytoplasm to the nucleus. Once in the nucleus, NFkB binds specific promoter elements of DNA and induces transcription of relevant genes. The specificity of NFkB for DNA promoter segments is dependent on nucleotide base sequences recognized by NFkB. The mediators under the control of NFkB include the proinflammatory cytokines TNFa and IL-1 (Collart and others 1990; Hiscott and others 1993), numerous chemokines (Widmer and others 1993), and many vascular endothelial cell adhesion molecules (Collins and others 1995). Obviously, the next logical step pursuant to the findings described above was to determine whether NFkB was involved in inflammatory responses in vivo.
Use of Rodent Models to Delineate the Role of NFkB during Inflammatory Reactions in Vivo
As outlined in Figure 1, the use of rodent models has allowed identification of many of the mediators involved in the development of acute inflammatory injury. The next objective was to apply the knowledge gained from in vitro studies of NFkB to determine whether this transcription factor was involved in the inflammatory response occurring in complex organ systems. Initial studies in a rat model of systemic inflammation induced by intraperitoneal injection of bacterial lipopolysaccharide demonstrated that activation of NFkB occurred in numerous tissues (Blackwell and others 1994; Essani and others 1996; Manning and others 1995). In addition, these studies showed that expression of chemokines and adhesion molecule mRNA was associated with NFrd3 activation. Subsequent studies of more carefully controlled models of inflammation helped characterize the precise role of NFkB during inflammation of different organs.
NFkB Activation during Acute Lung Inflammation
Using a rat model of lung inflammation induced by intra-pulmonary deposition of IgG immune complexes, the precise time course of NFkB activation during lung injury has been documented (Lentsch and others 1997, 1998b). In this model, alveolar macrophages (obtained by bronchoalveolar lavage) are activated by the inflammatory insult (that is, IgG immune complexes) and rapidly demonstrate increased nuclear translocation of NFkB. The activation of NFkB in alveolar macrophages is associated with enhanced production of the proinflammatory cytokines TNFa and IL-1 (Mulligan and Ward 1992). These cytokines are known to cause upregulation of chemokines and vascular adhesion molecules within the lung (Mulligan and others 1993; Shanley and others 1997). When either TNFa or IL- 1 was neutralized using blocking antibodies, lung NFkB activation was greatly attenuated (Lentsch and others 1998b). Furthermore, when alveolar macrophages were depleted using liposome-encapsulated dichloromethylene diphosphonate, lung NFkB activation was virtually abolished (Lentsch and others 1998a). In rats depleted of alveolar macrophages, lung instillation of TNFa caused activation of NFkB in whole lung tissues. These studies suggest that during acute inflammatory lung injury, activation of NFkB in alveolar macrophages may be responsible for proinflammatory cytokine production. These proinflammatory cytokines appear to propagate the inflammatory response in lung by activating NFkB in other lung cell types, possibly resulting in the expression of chemokines and vascular adhesion molecules in a variety of cell types.
The importance of NFkB activation during lung inflammation has also been demonstrated in studies employing agents that specifically inhibit the nuclear translocation of NFkB. In vitro, antioxidants prevent the phosphorylation and degradation of IkB and limit the extent of nuclear translocation of NFkB (Ghosh and others 1998). In vivo administration of the antioxidant N-acetylcysteine suppressed lung NFkB activation induced either by intraperitoneal injection of lipopolysaccharide or by intrapulmonary deposition of lgG immune complexes (Blackwell and others 1996; Lentsch and others 1998b). Interestingly, it was found that another antioxidant, catalase, was incapable of inhibiting lung NFkB (Lentsch and others 1998b). Because N-acetylcysteine is a very small molecule (163 d) that easily diffuses across cell membranes and catalase is very large (~240 kDa) and probably does not gain cellular entry, it appears that only oxidants generated in the cytoplasm of lung cells are involved in the activation of NFkB.
The use of antioxidants in the study of NFkB is limited due to the relatively nonspecific nature of these agents. What is unclear in these studies is how the antioxidants affect NFkB activation. Furthermore, these agents also reduce tissue injury by scavenging the oxidants released from activated phagocytic cells. Thus, information from these studies regarding the role of NFkB in inflammatory injury is somewhat speculative. In contrast, other studies employing anti-inflammatory cytokines known to regulate the production of TNFa and IL-1 have suggested that NFkB may be central to the acute inflammatory response. Two of the most potent antiinflammatory cytokines, IL- 10 and IL- 13, greatly reduce lung inflammatory injury while almost completely suppressing activation of NFkB (Lentsch and others 1997). Inhibition of NFkB activation by both IL-10 and IL-13 was accomplished by preserving the cytoplasmic expression of the NFkB-inhibiting protein IkBb. These studies not only helped identify the in vivo antiinflammatory mechanisms of IL-10 and IL-13, but they also increased our understanding of the regulation of lung inflammatory injury. Both IL-10 and IL-13 are constitutively expressed in lung, and endogenous production of these cytokines serves as a negative feedback loop of the inflammatory response, potentially limiting the progression of inflammation by inhibiting NFkB activation (Lentsch and others 1999a). In other studies, a serine protease inhibitor, secretory leukocyte protease inhibitor (SLPP), was shown to suppress lung inflammatory injury as well as inhibit the activation of NFkB (Lentsch and others 1999b). These inhibitory effects of SLPI were associated with upregulation of the NFkB-inhibiting protein IkBb. Blockade of endogenous SLPI with antibody augmented the lung inflammatory response and enhanced activation of NFkB (Lentsch and others 1999b). These studies strongly suggest that endogenous IL-10, IL-13, and SLPI regulate the inflammatory response in vivo by their effects on NFkB activation.
NFkB Activation during Acute Liver Inflammation
The involvement of NFkB in acute liver inflammation induced by hepatic ischemia and repeffusion in rats and mice has also been evaluated. In these models, hepatic ischemia causes activation of liver macrophages (Kupffer cells). These cells release reactive oxygen species and proinflammatory cytokines, including TNFa, which may directly injure liver parenchymal (hepatic) cells. However, enhanced production of TNFa plays a more important role in the initiation of a cascade of events leading to the later phase of liver injury, which is mediated by neutrophils (Figure 1). One of the main functions of TNFa is the hepatic upregulation of adhesion molecules and neutrophil-attracting chemokines (Colletti and others 1995, 1998; Lentsch and others 1998c). The coordinated actions of adhesion molecules and chemokines mediate the recruitment of neutrophils into the liver. Sequestered neutrophils release proteases and reactive oxygen intermediates, which directly damage hepatocytes and endothelial cells and also contribute to capillary plugging, causing hepatic hypoperfusion (Jaeschke and others 1996; Vollmar and others 1996).
Using this model, activation of NFkB in the liver was shown to occur shortly after repeffusion (Bradham and others 1997; Yoshidome and others 1999; Zwacka and others 1998a). Although the details of cell-specific NFkB activation have not yet been delineated in this model of inflammation, the time course of activation is consistent with upregulation of vascular cell adhesion molecules and chemokines within the liver (Colletti and others 1998; Lentsch and others 1998c). Similar to studies of lung inflammation, treatment with anti-oxidants reduced liver injury in association with suppressed activation of NFkB (Zwacka and others 1998b). In addition, investigations of IL-10 and SLPI demonstrate that these antiinflammatory mediators also reduce hepatic ischemia/ reperfusion injury through effects on NFkB (Lentsch and others 1999c; Yoshidome and others 1999). These effects are of interest because unlike the lung in which NFkB activation is associated with degradation of IkBa (Lentsch and others 1997, 1998b), activation of NFkB during hepatic ischemia/reperfusion occurs without measurable degradation of either IkBa or IkBb (Zwacka and others 1998a). A possible explanation is that exogenously administered IL-10 or SLPI may augment production of BcB proteins as a mechanism of their inhibitory effects on NFkB. However, whether endogenous production of these mediators regulates NFkB activation and liver inflammatory injury remains to be determined.
Conclusion
The use of rodent models of inflammation has allowed detailed investigation into some of the earliest events in the induction of the acute inflammatory response. Because transcription factors such as NFkB control gene expression of mediators at every level of the inflammatory response (proinflammatory cytokines, chemokines, adhesion molecules), knowledge gained from work done in animal models offers valuable therapeutic potential. Furthermore, these models have provided information critical to a more complete understanding of the regulation of inflammatory processes. It is very interesting that antiinflammatory mediators as diverse in function as cytokines (IL-10 and IL-13) and a protease inhibitor (SLPI) may suppress inflammatory responses through effects on a single transcription factor (NFkB). Investigations of these mediators have also been performed in vitro, and although IL-10 and IL-13 suppress NFkB activation in monocytes and macrophages, SLPI does not (Lentsch and others 1999b). These types of findings illustrate the necessity for the use of rodents in inflammation research and emphasize the fact that in vitro studies are often inadequate for a reflection of the in vivo response.
1 Abbreviations used in this article: IgG, immunoglobulin G; Ir, B, inhibitory factor kappa B; IL, interleukin; NF~rB, nuclear factor kappa B; SLPI, secretory leukocyte protease inhibitor; TNFCt, tumor necrosis factor-ct.
References
Blackwell TS, Blackwell TR, Holden EP, Christman BW, Christman JW. 1996. In vivo antioxidant treatment suppresses nuclear factor-kappa B activation and neutrophilic lung inflammation. J Immunol 157:1630-1637.
Blackwell TS, Holden EP, Blackwell TR, DeLarco JE, Christman JW. 1994. Cytokine-induced neutrophil chemoattractant mediates neutrophilic alveolitis in rats: Association with nuclear factor kappa B activation. Am J Respir Cell Mol Biol 11:464-472.
Bradham CA, Stachlewitz RF, Gao W, Qian T, Jayadev S, Jenkins G, Hannun Y, Lemasters JJ, Thurman RG, Brenner DA. 1997. Repeffusion after liver transplantation in rats differentially activates the mitogen-activated protein kinases. Hepatology 25:1128-1135.
Caty MG, Guice KS, Oldham KT, Remick DG, Kunkel SL. 1990. Evidence for tumor necrosis factor-induced pulmonary microvascular injury after intestinal ischemia-reperfusion injury. Arm Surg 212:694-700.
Coilart MA, Baeuerle P, Vassalli P. 1990. Regulation of tumor necrosis factor alpha transcription in macrophages: Involvement of four kappa B-like motifs and of constitutive and inducible forms of NF-kappa B. Mol Cell Biol 10:1498-1506.
Colletti LM, Burtch GD, Remick DG, Kunkel SL, Strieter RM, Guice KS, Oldham KT, Campbell DA, Jr. 1990a. The production of tumor necrosis factor alpha and the development of a pulmonary capillary injury following hepatic ischemia/reperfusion. Transplantation 49:268-272.
Colletti LM, Cortis A, Lukacs N, Kunkel SL, Green M, Strieter RM. 1998. Tumor necrosis factor up-regulates intercellular adhesion molecule 1, which is important in the neutrophil-dependent lung and liver injury associated with hepatic ischemia and reperfusion in the rat. Shock 10:182-191.
Colletti LM, Kunkel SL, Walz A, Burdick MD, Kunkel RG, Wilke CA, Strieter RM. 1995. Chemokine expression during hepatic ischemia/ reperfusion-induced lung injury in the rat. The role of epithelial neutro-phil activating protein. J Clin Invest 95:134-141.
Colletti LM, Remick DG, Burtch GD, Kunkel SL, Strieter RM, Campbell DA, Jr. 1990b. Role of tumor necrosis factor-alpha in the pathophysi-ologic alterations after hepatic ischemia/reperfusion injury in the rat. J Clin Invest 85:1936-1943.
Collins T, Read MA, Neish AS, Whitley MZ, Thanos D, Maniatis T. 1995. Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers. FASEB J 9:899-909.
DiDonato JA, Hayakawa M, Rothwarf DM, Zandi E, Karin M. 1997. A cytokine-responsive IkB kinase that activates the transcription factor NFkB. Nature 388:548-554.
Essani NA, McGuire GM, Manning AM, Jaeschke H. 1996. Endotoxin-induced activation of the nuclear transcription factor kappa B and expression of E-selectin messenger RNA in hepatocytes, Kupffer cells, and endothelial cells in vivo. J Immunol 156:2956-2963.
Ghosh S, May MJ, Kopp EB. 1998. NFkB and Rel proteins: Evolutionary conserved mediators of immune responses. Annu Rev Immunol 16:225-260.
Hiscott J, Marois J, Garoufalis J, D'Addario M, Roulston A, Kwan I, Pepin N, Lacoste J, Nguyen H, Bensi G. 1993. Characterization of a functional NF-kappa B site in the human interleukin I beta promoter: Evidence for a positive autoregulatory loop. Mol Cell Biol 13:6231-6240.
Huguet C., GavelIi A,Bona S. 1994. Hepatic resection with ischemia of the liver exceeding one hour. J Am Coil Surg 178:454-458.
Jaeschke H, Farhood A, Bautista AP, Spolarics Z, Spitzer JJ. 1993. Complement activates Kupffer cells and neutrophils during reperfusion after hepatic ischemia. Am J Physiol 264:G801-G809.
Jaeschke H, Farhood A, Smith CW. 1990. Neutrophils contribute to ischemia/reperfusion injury in rat liver in vivo. FASEB J 4:3355-3359.
Jaeschke H, Smith CW, Clemens MG, Ganey PE, Roth RA. 1996. Mechanisms of inflammatory liver injury: Adhesion molecules and cytotoxicity of neutrophils. Toxicol Appl Pharmacol 139:213-226.
Johnson KJ, Ward PA. 1974. Acute immunologic pulmonary alveolitis. J Clin Invest 54:349-357.
Lechner A J, Ryerse JS, Matuschak GM. 1993. Acute lung injury during bacterial or fungal sepsis. Microsc Res Tech 26:444-456.
Lemasters J J, Thurman RG. 1997. Reperfusion injury after liver preservation tor transplantation. Annu Rev Pharmacol Toxicol 37:327-338.
Lentsch AB, Czermak BJ, Bless NM, Van Rooijen N, Ward PA. 1998a. Essential role of alveolar macrophages in intrapulmonary activation of NF-kappaB. Am J Respir Cell Mol Biol 20:692 698.
Lentsch AB, Czermak BJ, Bless NM, Ward PA. 1998b. NF-kappa B activation during IgG immune complex induced lung injury: Requirements for TNF-alpha and IL- I beta but not complement. Am J Pathol 152:1327-1336.
Lentsch AB, Czermak B J, Jordan J, Ward PA. 1999a. Regulation of lung inflammatory injury by endogenous interleukin-13. J Immunol 162:1071-1076.
Lentsch AB, Jordan J, Czermak BJ, Diehl KM, Sarma V, Ward PA. 1999b. Inhibition of NF kappa B and augmentation of I kappa B beta by secretory leukocyte protease inhibitor during lung inflammation. Am J Pathol 154:239-247.
Lentsch AB, Shanley TP, Sarma V, Ward PA. 1997. In vivo suppression of NF-kappa B and preservation of I kappa B alpha by interleukin-10 and interleukin-13. J Clin Invest 100:2443-2448.
Lentsch AB, Yoshidome H, Cheadle WG, Miller FN, Edwards MJ. 1998c. Chemokine involvement in hepatic ischemia/reperfusion injury in mice: Roles for macrophage inflammatory protein-2 and KC. Hepatology 27:1172-1177.
Lentsch AB, Yoshidome H, Warner RL, Ward PA, Edwards MJ. 1999c. Secretory leukocyte protease inhibitor regulates local and remote organ inflammatory injury induced by hepatic ischemia/reperfusion. Gastroenterology (Forthcoming).
Manning AM, Bell FP, Rosenbloom CL, Chosay JG, Simmons CA, Northrup JL, Shebuski RJ, Dunn CJ, Anderson DC. 1995. NF-kappa B is activated during acute inflammation in vivo in association with elevated endothelial cell adhesion molecule gene expression and leukocyte recruitment. J Inflamm 45:283-296.
Mulligan MS, Vaporciyan AA, Miyasaka M, Tamatani T, Ward PA. 1993. Tumor necrosis factor alpha regulates in vivo intrapulmonary expression of ICAM- 1. Am J Pathol 142:1739-1749.
Mulligan MS, Ward PA. 1992. Immune complex-induced lung and dermal vascular injury. Differing requirements for tumor necrosis factor-alpha and IL-I. J Immunol 149:331-339.
Perkins ND, Schmid RM, Duckett CS, Leung K, Rice NR, Nabel GJ. 1992. Distinct combinations of NF-kappa B subunits determine the specificity of transcriptional activation. Proc Natl Acad Sci U S A 89:1529-1533.
Schall TJ, Bacon KB. 1994. Chemokines, leukocyte trafficking, and inflammation. Curr Opin Immunol 6:865-873.
Shanley TP, Schmal H, Warner RL, Schmid E, Friedl HP, Ward PA. 1997. Requirement for C-X-C chemokines (macrophage inflammatory protein-2 and cytokine-induced neutrophil chemoattractant) in IgG immune complex-induced lung injury. J Immunol 158:3439-3448.
Simons RK, Junger WG, Loomis WH, Hoyt DB. 1996. Acute lung injury in endotoxemic rats is associated with sustained circulating IL-6 levels and intrapulmonary CINC activity and neutrophil recruitment: Role of circulating TNF-alpha and 1L-lbeta? Shock 6:39-45.
Springer TA. 1990. Adhesion receptors of the immune system. Nature 346:425-434.
Springer TA. 1994. Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm. Cell 76:301-314.
Varani J, Ginsburg I, Schuger L, Gibbs DF, Bromberg J, Johnson KJ, Ryan US, Ward PA. 1989. Endothelial cell killing by neutrophils. Synergistic interactions of oxygen products and proteases. Am J Pathol 135:435-438.
Vedder NB, Fouty BW, Winn RK, Harlan JM, Rice CL. 1989. Role of neutrophils in generalized reperfusion injury associated with resuscitation from shock. Surgery 106:509-516.
Vollmar B, Richter S, Menger MD. 1996. Leukocyte stasis in hepatic sinu-soids. Am J Physiol 270:G798oG803.
Ward PA. 1996. Role of complement in lung inflammatory injury. Am J Pathol 149:1081 - 1086.
Widmer U, Manogue KR, Cerami A,Sherry B. 1993. Genomic cloning and promoter analysis of macrophage inflammatory protein (MIP)-2, MIP- 1 alpha, and MIP-1 beta, members of the chemokine superfamily of proinflammatory cytokines. J Immunol 150:4996-5012.
Yoshidome H, Kato A, Edwards MJ, Lentsch A. 1999. lnterleukin-10 suppresses hepatic ischemia/repeffusion itljury in mice: Implications for a central role of NF~cB. Hepatology 30:203-208.
Zwacka RM, Zhang Y, Zhou W, Halldorson J, Engelhardt JF. 1998a. Ischemia/Reperfusion injury in the liver of BALB/c mice activates AP-l and nuclear factor kappa B independently of lkappaB degradation. Hepatology 28:1022-1030.
Zwacka RM, Zhou W, Zhang Y, Darby CJ, Dudus L, Halldorson J, Oberley L, Engelhardt JF. 1998b. Redox gene therapy for ischemia/reperfusion injury of the liver reduces AP 1 and NF-kappa B activation. Nature Med 4:698-704.
(infection; ischemia, trauma, etc.)
¯
Complement Activation
¯
Macrophage Activation
¯
Release of TNFct and IL-I
¯
Upregulation of Vascular Cell Adhesion Molecules and Chemokines Tissue Recruitment of Neutrophils
¯
Neutrophil and Macrophage-derived Oxidants and Proteases
¯
Figure 1 Common pathway of acute inflammatory tissue injury. TNFa, tumor necrosis factor-a; IL, interleukin.
Figure 2 Mechanism of NFkB activation. IkB, inhibitory factor kappa B; NFkB, nuclear factor kappa B.
Copyright © 2008. National Academy of Sciences.
All rights reserved.
500 Fifth St. N.W., Washington, D.C. 20001.
Terms of Use and Privacy Statement